ExonHit has developed its own therapeutic pipeline based on its unique gene to drug discovery process. We have clinical-stage programs in Alzheimer's disease and pain and early-stage programs in a variety of indications.
Navigation
Allergan
In December 2002, ExonHit and Allergan launched a strategic alliance to discover drugs in the fields of ophthalmology, pain and neurodegenerative diseases.
Since its inception, the partnership has been extended 3 times in duration and expanded in scope. Our drug discovery activities are based on findings from ExonHit’s DATAS™ and SpliceArray™ technologies, from which both companies identify novel targets and generate new compounds for further development and commercialization by Allergan.
Other partnerships
While our primary focus is currently on finding a global partner to develop our lead product EHT 0202 for the treatment of Alzheimer’s disease, we are also looking for partners to support a variety of small molecule programs. These are at earlier stages of development, ranging from lead identification to proof of concept in relevant animal models.
ExonHit is also keen to build partnerships around epitope discovery for the development of antibody therapeutics. ExonHit’s SpliceArray™ technology is ideally suited for rapidly identifying splice events that code for novel peptide sequences (or epitopes) and specifically those expressed in disease tissue that are appropriate for targeting with antibodies. Such epitopes offer the potential benefit of being both highly specific and unburdened by existing intellectual property rights.
For any partnering inquiries, please contact William Vickery at: william.vickery@exonhit.com